問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Principal Investigator

Principal Investigator


National Taiwan University Hospital (在職)

Division of Cardiovascular Diseases

Division of General Internal Medicine

E-DA Hospital

更新時間：2024-03-27

吳造中Wu, Chau-Chung
  • Principal Investigator
  • Clinical Trial Experience (year) 23 years 10 個月

  • r204.cc01@gmail.com

Recruiting Trial

7Cases

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

吳造中

List

13Cases

2023-10-02 - 2030-09-30

Phase III

Active

  • Condition/Disease

  • Test Drug

Participate Sites
10Sites

Recruiting10Sites

2023-07-01 - 2026-01-31

Phase III

Completed

  • Condition/Disease

  • Test Drug

Participate Sites
7Sites

Recruiting7Sites

2024-05-01 - 2029-12-31

Phase III

Active

  • Condition/Disease

  • Test Drug

Participate Sites
10Sites

Recruiting10Sites

2023-06-20 - 2026-06-30

Phase III

Completed

  • Condition/Disease

  • Test Drug

Participate Sites
4Sites

Recruiting4Sites

2024-06-01 - 2027-12-31

Phase III

Active

  • Condition/Disease

  • Test Drug

Participate Sites
4Sites

Recruiting4Sites

2007-02-01 - 2008-04-30

Phase III

Not yet recruiting

  • Condition/Disease

  • Test Drug

Participate Sites
5Sites

Terminated5Sites

2021-05-18 - 2026-08-21

Phase III

Active

  • Condition/Disease

  • Test Drug

Participate Sites
7Sites

Recruiting7Sites

2013-12-15 - 2016-12-31

Phase III

Completed

  • Condition/Disease

  • Test Drug

Participate Sites
7Sites

Terminated7Sites

2012-02-01 - 2015-12-31

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
4Sites

Terminated4Sites

2013-01-10 - 2015-12-31

Phase III

A 24-Week, Worldwide, Multicenter, Double-Blind, Randomized, Parallel, Placebo- Controlled Study to Assess the Efficacy and Tolerability of Anacetrapib When Added to Ongoing Statin Therapy With or Without Other Lipid Modifying Medication(s) in Patients With Hypercholesterolemia or Low HDL-C

  • Condition/Disease

    Hyperlipidemia

  • Test Drug

    MK859/Placebo

Participate Sites
9Sites

Terminated9Sites

1 2
聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB